CEF in SP CDM

CellCrine

Single BioActivated Protein Chemically Defined Medium supplement (BAP SP CDM) suitable for all cell types.

We have developed a groundbreaking BAP SP Chemically Defined Medium (SP-CDM) that outperforms Fetal Bovine Serum (FBS).

CellCrine’s mission is to apply and validate BAP SP CDM across all cell types.

The Chemically Defined Media (CDM) market is currently poised for significant growth, with projections expected to exceed $4 billion by 2026.

As the biopharmaceutical, cell therapy, and regenerative medicine sectors continue to expand, the demand for high-quality, consistent, and scalable culture media has become increasingly critical to emerging trends in personalized medicine, laboratory automation, and sustainability. Given its foundational role in bioprocessing, the CDM market remains a strategic focus for investors and corporations.

At CellCrine, we are dedicated to understanding and harnessing the power of cells.

Our biochemical, structural, and functional research into secreted factors has enabled us to develop a Single BioActivated Protein Chemically Defined Medium supplement (BAP SP CDM) suitable for all cell types.

By identifying and optimizing critical media components that induce potent cell signaling, we have successfully utilized a single BAProtein to eliminate the need for traditional growth factors. Our BAP SP CDM has been validated on more than 20 different cell types, including Tuna, CHO, MDCK, MRC5, HeLa, HEK293, Bovine, Porcine, Chicken, Stem cells, Vero, CEF/DF1, and iBSC.

Cracking the code

CellCrine is proud to announce a significant milestone following 30 years of dedicated research and development. We have developed a groundbreaking BAP SP Chemically Defined (SP-CDM) technology that consistently outperforms Fetal Bovine Serum (FBS).

Our BAP SP-CDM allows cells to be seeded in scaffolds and standard cell culture-grade vessels, providing the essential nutrients and building blocks needed to thrive and exceed the performance of FBS.

Cultivated meat companies currently face the challenge of entering cost-sensitive markets where consumer loyalty to traditional animal products remains high. To succeed, these companies require a scaling strategy that prioritizes long-term profitability through competitive pricing and superior taste. CellCrine developed BAP SP-CDM specifically to address these hurdles and make cultivated meat a market reality.

Our goal is to provide the most cost-effective CDM to the CMI, BioPharma, and scientific communities.

For more information, please contact us at: info@cellcrine.com.